News Search
|
All News Topics
>
Canadian Space Agency
;
Press Releases by Industry Channel
>
All Canadian Space Agency Press Releases
Integral BioSystems to Exhibit in Booth 2721 at 2018 BIO International Convention in Boston June 5-7, 2018
Boston area drug developer Integral BioSystems to display in Booth 2721 at the 2018 BIO International Convention in the Boston Convention Center June 5-7, 2018
If you need the most effective formulation, you need Integral BioSystems.”
BEDFORD, MA, US, May 30, 2018 /EINPresswire.com/ -- Integral BioSystems LLC, Boston area CRO specializing in innovative pharmaceutical formulation development, will be in the spotlight as a participating exhibitor during the 2018 BIO International Convention in the Boston Convention Center, beginning at 10 AM on June 5-7, 2018.— Dr. Shikha Barman
With over 25 years of experience in all phases of cell and tissue targeted, sustained release pharmaceutical formulation development, the firm’s CEO and President, Dr. Shikha P. Barman, will be on hand to discuss the specific requirements of interested attendees.
About the Symposium
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
The key benefits of attending the 2018 BIO International Convention are access to global biotech and pharma leaders, exposure to industry thought-leaders with over 500 education sessions, and networking opportunities with 16,000+ attendees and exhibitors from 74 countries.
About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.
The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.
For those seeking to develop a formulation for a new drug substance, a 505b2 product or a generic drug product, Dr. Barman will be available to answer questions about possible strategies for your particular application.
Dave Karasic
Integral BioSystems, LLC
617-820-8483
email us here
Powered by
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
